Company intelligence / Profile preview
Omeza
Sarasota, Florida, United Statesomeza.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Commercial
01
Overview
Omeza’s OCM™ Wound Matrix has demonstrated positive interim results in clinical trials for diabetic foot ulcers, achieving a 91% area reduction within twelve weeks and a 63% reduction within four weeks. The product is FDA-cleared via the 510(k) pathway and is being evaluated in real-world settings and additional clinical studies targeting chronic non-healing wounds of various etiologies. The company is commercial-stage with products available to healthcare providers.
- Therapeutic areas
- OtherDermatologyCardiovascularEndocrinology
- Modalities
- Drug-device combination productBiologic (marine-based peptides and omega fatty acids)Device (wound matrix)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Omeza.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omeza.